Plain-English translation of NCT07288151 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Post Traumatic Stress Disorder research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether MDMA, when combined with a well-established therapy called Prolonged Exposure, can help people with PTSD get better faster and more completely. You would receive ten therapy sessions over two weeks, and during one of those sessions, you would take either the medication or a placebo (inactive pill). The study aims to see whether the medication makes the therapy more effective by measuring your PTSD symptoms one month after treatment ends.
Many people with PTSD don't fully recover with therapy or medication alone, and current treatments often have limited success. Early research suggests that this medication might help people process traumatic memories more effectively during therapy, potentially leading to better outcomes.
You likely qualify if…
You likely don't qualify if…
You would attend ten therapy sessions over two weeks, where you would talk with a therapist about your trauma using a proven approach called Prolonged Exposure. During your second therapy session, you would take either the study medication or a placebo pill. You would need to follow specific instructions before that session (like fasting), arrange for someone to drive you home afterward, and allow your study visits to be recorded. One month after your treatment ends, you would complete a final assessment where a clinician interviews you about your PTSD symptoms.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States